AU2013200971B2 - Pharmaceutical compositions of rhein or diacerein - Google Patents

Abstract

Abstract The invention relates to pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50*. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools as compared to Art 50*. The invention also relates to the methods for preparing such compositions.

Description

P/00/011 Regulation 3.2 AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION FOR A DIVISIONAL PATENT ORIGINAL Name of Applicant: WOCKHARDT LIMITED Actual Inventors: JAIN, Girish Kuamr THAKKAR, Vikrant SANDAL, Roshanlal DABRE, Rahul Address for Service: Houlihan 2 Level 1, 70 Doncaster Road Balwyn North Victoria 3104 Australia Invention Title: PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN The following statement is a full description of this invention, including the best method of performing it known to the Applicant:- PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN The present application is a divisional application from Australian patent application number 2008303277. The entire disclosures of Australian patent 5 application number 2008303277 and its corresponding International application, PCT/IB2008/053750, are incorporated herein by reference. Field of the Invention 10 The invention relates to pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50*. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools as compared to Art 50*. 15 The invention also relates to methods for preparing such compositions. Background of the Invention Chemically, rhein is 9,1 0-dihydro-4, 5-dihydroxy-9, 1 0-dioxo-2-anthracene 20 carboxylic acid having a structure of Formula I and diacerein is 4,5-bis (acetyloxy) 9,1 0-dihydro-4, 5-dihydroxy-9, 1 0-dioxo-2-anthracenecarboxylic acid having a structure of Formula II. Diacerein is widely used in the treatment of osteoarthritis and has a unique mode of action that differentiates it from non-steroidal anti inflammatory drugs (NSAIDs) and other conventional forms of drug therapy. 25 Presently, diacerein capsules are available in 50 mg strength and are marketed by Negma in France and under the trade name Art 50*. OH 0 OH COOH 0 Formula-I 2 0 COOH

H

3 C 0 0 O H 0 0 Formula-Il Diacerein is practically insoluble in solvents such as water, alcohols, acetone, 5 dichloromethane and chloroform, which are generally used in pharmaceutical preparations. Although diacerein can be administered by oral route but it cannot be completely absorbed by the digestive tract, and this incomplete absorption may result in undesirable side effects such as, soft stools. 10 In order to overcome these problems, various derivatives, pharmaceutical compositions and specific galenic forms have been proposed in the literature. For example, European patent, EP 243,968 discloses a potassium salt of diacerein, which is water-soluble and can be used in the preparation of compositions for parenteral administration. 15 European Patent No EP904060 discloses pharmaceutical compositions of rhein or diacerein, wherein rhein or diacerein is co-micronized with sodium lauryl sulfate. European Patent Nos. EP263083; 264989 and 446753 disclose controlled release 20 or delayed release compositions like multiplicity of pellets coated with drug and coating membrane or granules of drug coated with polymers or loading polymeric particles of water swellable cross-linked polymer with drug. U.S. Patent Nos. 5,225,192 and 5,569,469 describe different poorly soluble 25 medicaments supported on polymeric particles of water swellable cross-linked polymer with drug. U.S. Patent No. 5,952,383 and European Patent No. EP 862423B1 describe pharmaceutical compositions of diacerein, rhein and their salts along with liquid 3 support systems like oils, suspending agents, homogenizing agents and other excipients. It is known that when 50 mg diacerein formulation currently marketed under the 5 trade name Art 50* is given orally in fasted conditions, due to fast gastric emptying, most of the diacerein remains unabsorbed and unabsorbed diacerein gets converted into rhein before reaching colon. At the colonic site, the rhein degrades to rhein-9-anthrone which causes significant soft stool effect. This soft stool effect is observed in about 50% of the patients after first few doses of Art 10 50*. In fact, about 30-40% soft stool effect is expected due to inherent pharmacokinetic property of diacerein, i.e diacerein undergoes enterohepatic circulation, wherein rhein gets conjugated in liver to form rhein-glucuronide, which on reaching colon gets converted to rhein-9-anthrone and hence causes soft stool effect. 15 On the other hand, when Art 50* is given in fed conditions, the gastric emptying is delayed in the presence of food. The longer residence time in upper part of the gastrointestinal tract accompanied with gastric fluids results in increased absorption of diacerein. This increase in absorption is up to 25% leading to 20 comparatively less amount of unabsorbed diacerein to reach colon and hence reduction in soft stools. However, this reduction in soft stools is not significant. It was also observed that when the diacerein formulation described in EP 904060 comprising co-micronized diacerein with sodium lauryl sulfate is given, it results in only about 18% reduction in soft stools, which is not significant. This reduction in 25 soft stools is not due to dose reduction but it is related to increased absorption of the diacerein leading to lesser amount of unabsorbed diacerein reaching colon. The diacerein formulation described in EP 904060 also exhibits drastic variation in both fed and fasted conditions. So, prior art formulations are discriminatory with respect to both fast and fed conditions. Additionally, prior art formulations are also 30 eclipsed with undesirable soft stool effect. Due to soft stool effect, prior art formulations (Art 50* and Art 40) are initially given once a day for about two months, so that the patient's gastrointestinal tract gets acclimatized to the side effect of diacerein. After that, the dosage regimen is 4 scheduled for twice a day for both Art 50* and Art 40. Although, this adjustment of the dosage regimen improves patient's compliance to some extent, but there is no reduction in side effects. There still exists a need to develop new formulations or compositions which are likely to achieve a higher rate and extent of absorption of 5 diacerein leading to improved bioavailability and at the same time shows significant reduction in side effects such as, soft stools. In spite of the attempts in the prior art, described above, the inventors are not aware of successful attempts to improve the absorption of diacerein and significant reduction in soft stools. As described below, the inventors have 10 surprisingly found that compositions of the invention result in a higher rate and extent of absorption from the gastrointestinal tract and significant reduction (at least 25%) in soft stools. The inventors also have surprisingly found that the compositions can be given with or without food without affecting the rate and extent of absorption. The inventors have further noticed that there is no need to 15 co-micronize diacerein with any surfactant to get a formulation, which is bioequivalent to the commercially available diacerein 50 mg solid oral dosage form (Art 50*). Thus, the compositions of the invention, overcome all the commonly encountered problems exemplified in the prior art. When the compositions of the invention are 20 given orally, diacerein gets completely absorbed in upper part of intestine and there remains no unabsorbed diacerein reaching colon, resulting in a significant reduction in soft stools effect from about 60-70%. Furthermore, the compositions of the invention are bioequivalent to 50 mg diacerein formulation currently marketed under the trade name Art 50* showing no variability whether 25 administered in fed or fasted state conditions. Summary of the Invention In one general aspect there is provided a melt granulated pharmaceutical 30 composition comprising rhein or diacerein, or salts or esters or prodrugs thereof. 5 The present invention provides use of rhein or diacerein, or salts or esters thereof, for the manufacture of a medicament for the treatment of osteoarthritis, wherein the said medicament is adapted for administration in a dosage form which comprises from about 20mg to about 45mg of rhein or diacerein, or salts or esters 5 or prodrugs thereof to a patient according to a dosage regimen comprising a dosing interval of twice daily from day one of therapy. In another general aspect there is provided a pharmaceutical composition comprising from about 20mg to about 45 mg of rhein or diacerein, or salts or 10 esters or prodrugs thereof, wherein the rhein or diacerein is melt granulated with pharmaceutically acceptable carriers, and wherein the composition exhibits no significant difference in one or both of the rate and the extent of absorption of the rhein or diacerein as compared to a 50 mg diacerein formulation marketed under the trade name Art 50*. 15 The composition can be taken with or without food. Embodiments of the pharmaceutical composition may include one or more of the following features. The pharmaceutical composition may further include one or 20 more pharmaceutically acceptable excipients. For example, the pharmaceutically acceptable excipients may include one or more of fillers, binders, lubricants, sweeteners, colors, disintegrants, surfactants, glidants, and the like. The pharmaceutical composition of the present invention can be present in the 25 form of a tablet, capsule, powder, disc, caplet, granules, pellets, granules in capsule, minitablets, minitablets in capsule, pellets in capsule, sachet and other dosage forms suitable for oral administration. In another general aspect there is provided a process for preparing a 30 pharmaceutical composition of rhein or diacerein, or salts or esters or prodrugs thereof, the process comprising mixing rhein or diacerein, or salts or esters or prodrugs thereof with one or more pharmaceutically acceptable carriers, and granulating the mixture by melting, mixing, congealing, optionally with one or more pharmaceutically acceptable excipients. 6 In another general aspect there is provided an immediate release wet granulated pharmaceutical composition comprising from about 20 mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof. 5 In another general aspect there is provided an immediate release wet granulated pharmaceutical composition comprising from about 20 mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, wherein the composition exhibits no significant difference in the rate and the extent of absorption of the rhein or diacerein or salts or esters or prodrugs thereof, as compared to a 50 mg 10 diacerein formulation currently marketed under the trade name Art 50*. The composition can be taken with or without food. Embodiments of the pharmaceutical composition may include one or more of the 15 following features. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients. For example, the pharmaceutically acceptable excipients may include one or more of fillers, binders, lubricants, sweeteners, colors, disintegrants, surfactants, glidants, and the like. 20 The pharmaceutical composition of the invention can be present in the form of tablet, capsule, powder, disc, caplet, granules, pellets, granules in capsule, minitablets, minitablets in capsule, pellets in capsule, sachet and other dosage forms suitable for oral administration. 25 In another general aspect there is provided a process for preparing an immediate release pharmaceutical composition comprising from about 20 mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, the process comprising: a) mixing rhein or diacerein, or salts or esters or prodrugs thereof with other 30 pharmaceutically acceptable excipients to form a premix; b) granulating the premix with one or more suitable solvents; and c) converting the granules into a suitable dosage form 7 In another general aspect there is provided a pharmaceutical composition comprising from about 20mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, wherein the particles have an average particle size from about 0.1 microns to about 30 microns. 5 In another general aspect there is provided an oral pharmaceutical composition comprising from about 20mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, wherein the particles have an average particle size from about 0.1 microns to about 30 microns, and the composition no significant 10 difference in the rate and the extent of absorption of the rhein or diacerein or salts or esters or prodrugs thereof as compared to that obtained by a 50 mg diacerein formulation marketed under the trade name Art 50*. The composition can be taken with or without food. 15 Embodiments of the pharmaceutical composition may include one or more of the following features. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients. For example, the pharmaceutically acceptable excipients may include one or more of fillers, binders, lubricants, sweeteners, glidants, disintegrants, and the like. 20 The pharmaceutical composition of the invention can be present in the form of tablet, capsule, powder, disc, caplet, granules, beads, sachet, suspension, pellets, spheroids, granules in capsule, minitablets, minitablets in capsule, pellets in capsule, sachet and other dosage forms suitable for oral administration. 25 In another aspect there is provided a method of making a pharmaceutical composition, the method comprising providing particles of rhein or diacerein, or salts or esters or prodrugs thereof, wherein the particles have an average particle size from about 0.1 microns to about 30 microns; forming a mixture by mixing the 30 particles of rhein or diacerein or salts or esters thereof with one or more pharmaceutically acceptable excipients; and forming the mixture into a pharmaceutical dosage form. 8 In another general aspect there is provided a modified release pharmaceutical composition comprising rhein or diacerein, or salts or esters or prodrug thereof. The modified release may be achieved either by one or more functional coatings 5 or mixing the rhein or diacerein, or salts or esters or prodrug thereof with one or more pharmaceutically acceptable polymers. In another general aspect there is provided a modified release pharmaceutical composition comprising rhein or diacerein, or salts or esters or prodrug thereof, 10 wherein the composition exhibits no significant difference in the rate and the extent of absorption of the rhein or diacerein as compared to 50 mg diacerein formulation marketed under the trade name Art 50*, and wherein the modified release is achieved by one or more functional coatings or mixing the rhein or diacerein, or salts or esters or prodrug thereof with one or more pharmaceutically 15 acceptable polymers. Embodiments of the pharmaceutical composition may include one or more of the following features. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients. For example, the pharmaceutically 20 acceptable excipients may include one or more of fillers, binders, lubricants, sweeteners, colors, disintegrants, surfactants, glidants, and the like. The pharmaceutical composition of the invention can be present in the form of a tablet, capsule, powder, disc, caplet, granules, beads, sachet, suspension, pellets, 25 spheroids, granules in capsule, minitablets, minitablets in capsule, pellets in capsule, sachet and other dosage forms suitable for oral administration. In another general aspect there is provided a process for preparing a modified release pharmaceutical composition comprising rhein or diacerein, or salts or 30 esters or prodrug thereof, the process comprising coating or mixing rhein or diacerein, or salts or esters or prodrug thereof with one or more pharmaceutically acceptable polymers, optionally with other pharmaceutical excipients and converting the mixture into a suitable dosage form. 9 In another general aspect there is provided a method of treatment of osteoarthritis, the method comprising providing a pharmaceutical dosage form comprising from about 20mg to about 45mg of rhein or diacerein, or salts or esters or prodrugs thereof to a patient twice daily from day one of therapy. 5 Embodiments of the pharmaceutical composition may include one or more of the following features. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients. For example, the pharmaceutically acceptable excipients may include one or more of fillers, binders, lubricants, 10 sweeteners, colors, disintegrants, surfactants, glidants, and the like. The pharmaceutical composition of the invention can be present in the form of a tablet, capsule, powder, disc, caplet, granules, beads, sachet, suspension, pellets, spheroids, granules in capsule, minitablets, minitablets in capsule, pellets in 15 capsule, sachet and other dosage forms suitable for oral administration. In another general aspect there is provided an oral pharmaceutical composition comprising from about 20mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, wherein the composition exhibits at least about 25% 20 reduction in soft stools as compared to a 50 mg diacerein formulation marketed under the trade name Art 50*. In another general aspect of the invention there is provided an oral pharmaceutical composition comprising 20 to 45 mg of rhein or diacerein, or salts 25 or esters or prodrugs thereof, wherein one or both of the rate and extent of absorption of the rhein or diacerein is equal or greater than that obtained by a 50 mg diacerein formulation marketed under the trade name Art 50*. The composition exhibits at least 25% reduction in soft stool effect as compared to a 50 mg diacerein formulation marketed under the trade name Art 50*. 30 Embodiments of the pharmaceutical composition may include one or more of the following features. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients. For example, the pharmaceutically 10 acceptable excipients may include one or more of fillers, binders, lubricants, sweeteners, colors, disintegrants, surfactants, glidants, and the like. In another general aspect of the invention there is provided an improved method 5 of treatment of osteoarthritis, the method comprising: a step of administering a dosage form comprising from about 20mg to about 45mg of rhein or diacerein, or salts or esters or prodrugs thereof to a patient according to an improved dosage regimen, wherein the improved dosage regimen consists of a dosing interval of twice 10 daily from day one of therapy. The pharmaceutical composition of the invention can be present in the form of tablet, capsule, powder, disc, caplet, granules, beads, sachet, suspension, pellets, spheroids, granules in capsule, minitablets, minitablets in capsule, pellets in 15 capsule, sachet and other dosage forms suitable for oral administration. The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. 20 Detailed Description of the Invention The inventors have developed various techniques for preparing rhein or diacerein compositions which are either bioequivalent or have increased bioavailability than 25 50mg diacerein composition commercially marketed under the trade name Art 50@. According to one embodiment, when rhein or diacerein is melt granulated with one or more pharmaceutically acceptable carriers, the obtained melt significantly 30 enhances the solubility of diacerein and percent drug release of diacerein as compared to Art 50@. Art 50@ releases about 14% of diacerein in 60 minutes, whereas the pharmaceutical composition of the invention releases 100% of diacerein in 30 minutes. This leads to increased bioavailability. The increased bioavailability further leads to reduction in side effects i.e. soft stools. The 11 administration of the composition to a human subject in a fasted state is bioequivalent to administration of the composition to a subject in fed state in particular, as defined by Cmax, Tmax and AUC guidelines given by the US Food and Drug Administration (US FDA) and European Medicines Agency (EMEA). 5 In one embodiment, a pharmaceutical composition of the invention may be prepared by melting one or more pharmaceutically acceptable carriers and mixing the diacerein with the molten mass, followed by congealing. The congealed solid 1la may be sized into granules. The granules may be mixed with other pharmaceutically acceptable excipients and may be formulated into a suitable dosage form. The diacerein may be mixed with the molten mass along with one or more surfactants. 5 Embodiments of the composition may include one or more of the following features. For example, the pharmaceutical composition may further include one or more pharmaceutically acceptable excipients selected from the group of fillers, lubricants, sweeteners, colors, disintegrants, surfactants and glidants. 10 Suitable pharmaceutically acceptable carriers include one or more of fatty esters, fatty acids and salts thereof, fatty alcohols, fatty amines, fatty amides, glycerides, glycolipids, steroids, natural and synthetic waxes, polyethylene glycol or its derivatives, and the like. 15 Polyethylene glycol or its derivatives may include PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG 6000, PEG 8000, PEG 20000, polyglycolyzed glycerides, polyethylene glycol-polyoxyethylenes, polyethylene glycol polypropylenes, polyethylene glycol-polyoxypropylenes. 20 Suitable fatty esters may include triglyceryl ester, glyceryl distearate, glyceryl tristearate, glyceryl monostearate, glyceryl dipalmitate, glyceryl tripalmitate, glyceryl monolaurate, glyceryl dodecosanoate, glyceryl tridecosanoate, glyceryl monodecosanoate, glyceryl monocaprate, glyceryl dicaprate, glyceryl tricaprate, 25 glyceryl monomyristate, glyceryl dimyristate, glyceryl trimyristate, glyceryl monodecanoate, glyceryl didecosanoate, glyceryl tridecosanoate, and the like. Suitable fatty acids may include acids having 12 to 28 carbons, e.g., stearic acid, palmitic acid, lauric acid, eleostearic acid, etc. Fatty alcohols may comprise 30 compounds having from 16 to 44 carbons, e.g., stearic alcohol, palmitol, etc. Glycerides may include monoglycerides, diglycerides, triglycerides, glycolipids, steroids and organic salts of fatty acids having from 12 to 29 carbons. Examples thereof comprise stearin, palmitin, castor wax, lecithin, hydrogenated cottonseed 12 oil, hydrogenated tallow, magnesium stearate and calcium and aluminum salts of palmitic and other fatty acids. Waxes may include paraffin wax, beeswax, carnauba, jojoba, microcrystalline, 5 palm, spermaceti, wool wax and other room temperature-solid hydrocarbon waxes. Suitable surfactants may include amphoteric, non-ionic, cationic or anionic surfactants. Suitable surfactants comprises one or more of sodium lauryl sulfate, 10 monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate (DOSS), lecithin, stearylic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, cremophore RH 40, and the like. 15 In yet another embodiment, the inventors have discovered that when rhein or diacerein, or salts or esters or prodrugs thereof is granulated with a suitable solvent or mixture of solvents, it results in a significant increase in the solubility of diacerein and increase in percent drug release of diacerein as compared to Art 20 50*. The Art 50* prepared by a dry compaction method releases about 14% of diacerein in 60 minutes, whereas the pharmaceutical composition of the present invention prepared by a wet granulation technique releases more than 65% of diacerein in 60 minutes. This results in increase in bioavailability and a significant reduction in side effects i.e. soft stools. The administration of the composition to a 25 human subject in a fasted state is bioequivalent to the administration of the composition to a subject in fed state in particular, as defined by Cmax, Tmax and AUC guidelines given by the US Food and Drug Administration (US FDA) and European Medicines Agency (EMEA). 30 According to one embodiment, a pharmaceutical composition can be prepared by mixing diacerein with other pharmaceutically acceptable excipients to form a premix; granulating the pre-mix with one or more suitable solvents; drying the granules; lubricating the granules and converting the final mixture into a suitable dosage form. 13 Suitable solvents include one or more of water, methanol, ethanol, isopropyl alcohol, acetone, methylene chloride, and the like. 5 The inventors have also found that when rhein or diacerein, or salts or esters or prodrugs thereof having an average particle size from about 0.1 microns to about 30 microns is used, it results in a significant increase in the solubility of diacerein, thus leading to increase in percent drug release of diacerein as compared to Art 50*. The Art 50* having a particle size of diacerein more than 43 microns releases 10 about 14% of diacerein in 60 minutes, whereas the pharmaceutical composition of the present invention having an average particle size of diacerein from 0.1 microns to 30 microns, in particular, from 0.2 micron to 20 microns releases 100% of diacerein in 15 minutes. The increase in bioavailability results in significant reduction in side effects i.e. soft stools. The administration of the composition to a 15 human subject in a fasted state is bioequivalent to administration of the composition to a subject in fed state in particular as defined by Cmax, Tmax and AUC guidelines given by US FDA and EMEA. The inventors have further found that there is no need to co-micronize diacerein 20 with any surfactant to get a formulation, which is bioequivalent to the commercially available diacerein 50 mg solid oral dosage form (Art 50*). Further, the compositions can be administered with or without food. The compositions of the invention result in a significant reduction of soft stools as a side effect, which is commonly encountered with Art 50*. 25 According to one embodiment, a pharmaceutical composition of the invention may be prepared by dispersing diacerein or salts thereof, optionally with pharmaceutically acceptable excipients in a suitable liquid dispersion medium and wet milling the dispersion through a suitable mill to get a suitable size. The 30 microparticulate dispersion of diacerein or salts thereof may be spray dried in a fluidized bed processor. The dried mixture may be mixed with other pharmaceutically acceptable excipients and may be converted into a suitable dosage form. 14 It was also found out by the inventors that the wet milling technique results in a better reduction of the particle size of diacerein or rhein. A smaller particle size up to 0.1 microns can be achieved with this technique which is otherwise difficult to achieve with a dry milling technique. Additionally, the wet milling prevents fuming 5 of dust particles and loss resulting from the same. Suitable liquid dispersion medium includes one or more of water, ethanol, isopropyl alcohol, butanol, hexane, glycols, vegetable oils, mineral oils, and the like. 10 Suitable means applied to reduce the particle size of rhein or diacerein or salts or esters or prodrugs thereof include one or more of nano mill, ball mill, attrition mill, vibratory mill, sand mill, bead mill, jet mill, dyno mill, ultrasonication, pressure homogenizer microfluidizer, and the like. 15 The inventors have also observed that when rhein or diacerein is present in an immediate release form, the rhein or diacerein gets immediately absorbed, resulting in a rapid elimination phase and hence decreased area under the plasma time curve (AUC). Additionally, the diacerein is also exposed to harsh 20 gastric conditions leading to degradation of the diacerein. The inventors have overcome this challenge by developing a modified release pharmaceutical composition comprising rhein or diacerein. The modified release pharmaceutical composition results in a prolonged absorption phase and increase in area under the plasma time curve (AUC), thus leading to increased bioavailability. Further, it 25 prevents the exposure of entire diacerein to harsh gastric conditions, hence preventing its degradation. Additionally, the modified release pharmaceutical composition of the invention is bioequivalent to a 50 mg of diacerein formulation commercially marketed under the trade name Art 50*. 30 The term 'modified release' as used herein includes extended release or delayed release or combinations thereof with immediate release in any percentage weight ratios. The term extended release may be used interchangeably with prolonged release, controlled release, slow release or sustained release. 15 The modified release composition may be administered in twice daily dosage regimen. The modified release in the pharmaceutical composition may be achieved by one 5 or more functional coatings or mixing the rhein or diacerein with one or more pharmaceutically acceptable polymers. The release may also be achieved by attachment of rhein or diacerein to ion exchange resins. The pharmaceutically acceptable polymers may include one or more of rate 10 controlling polymers, or enteric polymers. Suitable rate controlling polymers may include one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, shellac, rosin, 15 zein (prolamine from corn), a poly(meth)acrylate, microcrystalline cellulose or poly(ethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, hydroxypropyl cellulose, hydroxypropyl methyl 20 cellulose, carboxyvinyl polymers, and the like. Suitable enteric polymers may include one or more of polymerized gelatin, shellac, methacrylic acid copolymer type C NF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propionate phthalate, polyvinyl acetate 25 phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic acid polymers and copolymers like methyl acrylate, ethyl acrylate, methyl 30 methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters (Eudragit NE, Eudragit RL, Eudragit RS), and the like. The rhein or diacerein or salts or esters or prodrug thereof may be present in the form of powder, granules, pellets, beads, microtablets, minitablets and crystals. 16 "Bioequivalency" is established by a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under USFDA regulatory guidelines, or a 90% Cl for AUC of between 0.80 to 1.25 and a 90% Cl for Cmax of between 0.70 to 5 1.43 under the European regulatory guidelines (EMEA). The term "confidence interval" as used herein refers to the plain meaning known to ordinary skill in the art. The confidence interval refers to a statistical range with a specified probability that a given parameter lies within the range. 10 The term "covariance" as used herein refers to the plain meaning known to ordinary skill in the art. It is a statistical measure of the variance of two random variables that are observed or measured in the same mean time period. This measure is equal to the product of the deviations of corresponding values of the 15 two variables from their respective means. The bioequivalence studies were carried out between Art 50* and composition of the invention in both fed state and fasted state. The study was monitored in terms of Cmax, AUC, Tmax achieved with the test products and reference product (Art 20 50*). The compositions of the invention exhibits pharmacokinetic profile characterized by Cmax of about 3.15 to 6.0pg/ml, Tmax of about 2.4 to 5.0h, AUCO-t of about 16.4 to 40 pg.h/ml, AUCO of about 16.7 to 40 pg.h/ml. 25 At 90% confidence interval, the area under the concentration time curve (AUCo-t and /or AUCO) and maximum plasma concentration (Cmax) values of composition of the invention lies between 0.70 and 1.70 as compared to that obtained by a 50 mg diacerein formulation marketed under the trade name Art 50*. 30 The advantages of the compositions of the invention, include, but are not limited to: (1) smaller solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect; (3) increased bioavailability; (4) substantially similar pharmacokinetic profiles of the rhein or diacerein, compositions when 17 administered in the fed versus the fasted state; (5) bioequivalency of the diacerein compositions when administered in the fed versus the fasted state. The pharmaceutical compositions may include one or more pharmaceutically 5 acceptable excipients selected from the group of fillers, binders, lubricants, disintegrants, sweeteners, colors, glidants, surfactants, and the like. Suitable fillers may include one or more of microcrystalline cellulose, silicified microcrystalline cellulose, mannitol, calcium phosphate, calcium sulfate, kaolin, 10 dry starch, powdered sugar, and the like. Suitable binders may include one or more of povidone, starch, stearic acid, gums, hydroxypropylmethyl cellulose, and the like. 15 Suitable lubricants may include one or more of magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, glyceryl behenate, and the like. Suitable disintegrants may include one or more of starch, croscarmellose sodium, 20 crospovidone, sodium starch glycolate, and the like. Suitable glidants may include one or more of colloidal silicon dioxide, talc or cornstarch, and the like. 25 Suitable sweeteners may include sugars, aspartame, sodium saccharine, potassium acesulfame, neohesperidine, dihydrochalone, sucralose, monoammonium glycyrrhizinate, and mixtures thereof. The coloring agents of the present invention may be selected from any FDA 30 approved colors for oral use. The pharmaceutical composition of the present invention can be present in the form of granules, pellets, beads, spheroids, tablet, minitablet, microtablet, 18 capsule, granules in capsule, pellets in capsule, minitablet in capsule or combinations thereof. The invention is further illustrated by the following examples which are provided 5 merely to be exemplary of the invention and do not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention. Example 1: 10 Table 1 No Ingredients % Composition Part I 1 PEG 6000 40-60 Part II 2 Diacerein 10-60 4 Lactose 5-40 5 Croscarmellose sodium 10-25 6 Silicified microcrystalline cellulose 1-25 7 Magnesium stearate 1-15 Procedure: PEG 6000 was melted and mixed at 60-700C along with diacerein to form a homogenous dispersion followed by congealing while mixing at room temperature. The congealed solid was sized through a sieve to get granules of uniform size. The granules thus obtained were mixed with lactose, croscarmellose 15 sodium, silicified microcrystalline cellulose, lubricated with magnesium stearate and filled into hard gelatin capsules. Example 2: Table 2 No Ingredients % Composition Part I 1 PEG 6000 40-60 2 Poloxamer 5-40 Part II 3 Diacerein 10-60 4 Sodium lauryl sulfate 1-20 Part III 5 Silicified microcrystalline cellulose 1-25 6 Lactose 5-40 7 Croscarmellose sodium 1-40 8 Magnesium stearate 1-15 19 Procedure: Poloxamer and PEG 6000 were melted and mixed at 60-70OC along with diacerein, sodium lauryl sulfate to form a homogenous dispersion followed by congealing while mixing at room temperature. The congealed solid was sized through a sieve to get granules of uniform size. The granules thus obtained were 5 mixed with lactose, silicified microcrystalline cellulose, croscarmellose sodium and lubricated with magnesium stearate and filled into hard gelatin capsules. Table 3: Dissolution Data Time % drug released % drug released (min) (Art 50*) (Example-2) 5 3 38 10 4 74 15 5 88 20 7 97 30 9 100 45 11 100 60 14 100 10 For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as a medium. 15 Example 3: Table 4 S. No Ingredients Quantity (mg per tablet) Intragranular 1 Diacerein 44.00 2 Povidone 11.50 3 Lactose 220.30 4 Croscarmellose sodium 11.50 5 Colloidal silicon dioxide 5.75 6 Hydroxy propyl methyl cellulose 20.00 Extragranular 7 Colloidal silicon dioxide 5.75 8 Magnesium stearate 1.20 20 Procedure: Diacerein was mixed with lactose, croscarmellose sodium, colloidal silicon dioxide, hydroxypropylmethyl cellulose and granulated with aqueous solution of povidone. The granules were dried, mixed with colloidal silicon dioxide and lubricated with magnesium stearate and filled into hard gelatin capsules of a 5 suitable size. Table 5: Dissolution data Time % drug released % drug released (min) (Art 50*) (Example-3) 10 4 17 20 7 28 30 9 39 45 11 54 60 14 68 90 16 94 120 19 100 Table 5 provides the dissolution data for diacerein capsules prepared as per the 10 formula given in Table 4. For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as a medium. Example 4: 15 Table 6 S. No Ingredients Quantity (mg per tablet) Intragranular 1 Diacerein 45.00 2 Povidone 11.50 3 Lactose 219.30 4 Croscarmellose sodium 11.50 5 Colloidal silicon dioxide 5.75 6 Hydroxy propyl methyl cellulose 20.00 Extragranular 7 Colloidal silicon dioxide 5.75 8 Magnesium stearate 1.20 21 Procedure: Diacerein was mixed with lactose, croscarmellose sodium, colloidal silicon dioxide, hydroxypropylmethyl cellulose and granulated with aqueous solution of povidone. The granules were dried, mixed with colloidal silicon dioxide and lubricated with magnesium stearate and filled into hard gelatin capsules of a 5 suitable size. Table 7: Dissolution data Time % drug released % drug released (min) (Art 50*) (Example-4) 10 4 18 20 7 26 30 9 37 45 11 57 60 14 72 90 16 96 120 19 100 Table 7 provides the dissolution data for diacerein capsules prepared as per the 10 formula given in Table 6. For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as a medium. Table 8: Bioequivalence data of the composition of the invention against Art 50* 15 with respect to pharmacokinetic parameters S.N. Pharmacokinetic (Art 50*) Composition of the parameters invention 1 Cmax (pg/ml) 3.058 3.48 2 Tmax (h) 5.39 4.80 3 AUCo- (pgh/ml) 22.688 22.82 4 AUCo(pgh/ml) 22.816 23.62 22 Table-9: Bioequivalence data with respect to Test (Composition of the invention) to reference (Art 50*) Ratios (T/R ratios) at 90% Confidence Interval (C.I.) Pharmacokinetic 90% C.I. S.No Ratio % CV parameters Lower Upper 1 Cmax (pg/ml) 113.79 97.56 179.09 25.23 2 AUCo- (pgh/ml) 100.57 89.48 150.17 22.39 3 AUCo(pgh/ml) 103.51 85.26 148.29 23.79 Example 5: 5 Table 10 S.N. Ingredients %w/w Part-I 1 Diacerein 11.26 2 Povidone 5-40 3 Water q.s. Part-Il 4 Starch 10-50 5 Silicified microcrystalline 5-70 cellulose 6 Croscarmellose sodium 1-15 7 Magnesium stearate 0.1-3 Procedure: Diacerein and povidone was dispersed in sufficient quantity of water to get a uniform dispersion. The diacerein dispersion was passed through a pressure homogenizer one or more times to get a desired particle size (0.1 p). The 10 microparticulate dispersion was spray dried in glatt. The dried mass was blended with silicified microcrystalline cellulose, starch, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. 15 Example 6: Table 11 S.N. Ingredients %w/w Part-I 1 Diacerein 11.26 2 Povidone 5-40 3 Water q.s. ______ ~Part-Il__ __ __ _ 4 Lactose 10-50 23 5 Silicified microcrystalline cellulose 5-70 6 Croscarmellose sodium 1-15 7 Magnesium stearate 0.1-3 Procedure: Diacerein and povidone was dispersed in sufficient quantity of water to get a uniform dispersion. The diacerein dispersion was passed through a microfluidizer one or more times to get a desired particle size (0.8p). The 5 microparticulate dispersion was spray dried in glatt. The dried mass was blended with silicified microcrystalline cellulose, lactose, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. 10 Example 7: Table 12 S.N. Ingredients %w/w Part-I 1 Diacerein 9.50 2 Hydroxypropyl methyl cellulose 10-50 3 Water q.s. Part-Il 4 Povidone 5-40 5 Silicified microcrystalline cellulose 5-70 6 Croscarmellose sodium 1-15 7 Magnesium stearate 0.1-3 Procedure: Diacerein and povidone was dispersed in sufficient quantity of water to get a uniform dispersion. The diacerein dispersion was passed through a pressure 15 homogenizer one or more times to get a desired particle size (5p). The microparticulate dispersion was spray dried in glatt. The dried mass was blended with silicified microcrystalline cellulose, microcrystalline cellulose, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. 20 Example 8: Table 13 S.N. Ingredients %w/w Part-I 1 Diacerein 9.50 24 2 Microcrystalline cellulose 5-40 3 Water q.s. Part-Il 4 Starch 10-50 5 Silicified microcrystalline cellulose 5-70 6 Croscarmellose sodium 1-15 7 Magnesium stearate 0.1-3 Procedure: Diacerein and hydroxypropylmethyl cellulose was dispersed in sufficient quantity of water to get a uniform dispersion. The diacerein dispersion was passed through a pressure homogenizer one or more times to get a desired particle size (12p). The microparticulate dispersion was spray dried in glatt. The 5 dried mass was blended with silicified microcrystalline cellulose, starch, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. Example 9: 10 Table 14 S.N. Ingredients %w/w Part-I 1 Diacerein 11.80 2 Povidone 5-40 3 Water q.s. Part-Il 4 Sucrose 10-50 5 Starch 10-50 6 Silicified microcrystalline cellulose 5-70 7 Croscarmellose sodium 1-15 8 | Magnesium stearate 0.1-3 Procedure: Diacerein and hydroxypropylmethyl cellulose was dispersed in sufficient quantity of water to get a uniform dispersion. The diacerein dispersion was passed through a pressure homogenizer one or more times to get a desired 15 particle size (15p). The microparticulate dispersion was spray dried in glatt. The dried mass was blended with sucrose, silicified microcrystalline cellulose, starch, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. 20 Example 10: 25 Table 15 S.N. Ingredients %w/w Part-I 1 Diacerein 12.50 2 Hydroxypropyl methyl 5-40 cellulose 3 Water q.s. Part-Il 4 Sucrose 10-50 5 Starch 10-50 6 Silicified microcrystalline 5-70 cellulose 7 Croscarmellose sodium 1-15 8 Magnesium stearate 0.1-3 Procedure: Diacerein and povidone was dispersed in sufficient quantity of water to get a uniform dispersion. The diacerein dispersion was passed through a 5 microfluidizer one or more times to get a desired particle size (22p). The microparticulate dispersion was spray dried in glatt. The dried mass was blended with sucrose, silicified microcrystalline cellulose, starch, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. 10 Table 16: Dissolution data Time % Drug released % Drug released Tie (Art 50* with particle size more (Composition of the invention (mi) than 43p) with particle size from 0.1- 30p) 5 3 55 10 4 93 15 5 100 20 7 100 30 9 100 45 11 100 60 14 100 For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as medium. 15 Table-1 7: Bioequivalence data of the composition of the invention against Art 50* with respect to pharmacokinetic parameters 26 S.N. Pharmacokinetic Art 50 Composition of the parameters invention 1 Cmax (pg/ml) 3.058 4.050 2 Tmax (h) 5.39 4.47 3 AUCo-t (pgh/ml) 22.688 25.559 4 AUCo(pgh/ml) 22.816 25.675 Table 18: Bioequivalence data with respect to Test (Composition of the invention) to reference (Art 50*) Ratios (T/R ratios) at 90% Confidence Interval (C.I.) S.No Pharmacokinetic Ratio 90% C.I. % CV parameters Lower Upper 1 Cmax (pg/ml) 132.42 99.59 176.08 27.73 2 AUCo-t (pgh/ml) 112.65 87.42 145.17 24.59 3 AUCs(pgh/mi) 112.53 87.16 145.29 24.77 5 Example 11: Table 19 S.N. Ingredients Mg per tablet Part-I 1 Diacerein 44.00 2 Povidone 50.00 3 Docusate sodium 7.00 4 Sodium lauryl sulfate 8.00 5 Starch 160.00 6 Silicified microcrystalline cellulose 30.00 7 Water q.s. Part-Il 8 Silicified microcrystalline cellulose 79.00 9 Croscarmellose sodium 20.00 10 Magnesium stearate 2.00 Procedure: Povidone was dissolved in water to obtain a clear solution. Diacerein 10 was dispersed in the above mentioned povidone solution to form a uniform dispersion. The diacerein dispersion was passed through a pressure homogenizer one or more times to get a desired particle size (0.9p). Sodium docusate was dissolved in water to obtain a clear solution and this clear solution was added to the microparticulate dispersion of diacerein and the dispersion was spray dried in 15 glatt on starch and silicified microcrystalline cellulose. The dried mass was 27 blended with silicified microcrystalline cellulose, croscarmellose sodium, lubricated with magnesium stearate and lubricated blend was filled into hard gelatin capsules of a suitable size. 5 Table 20: Dissolution data Time % Drug released % Drug released (min) (Art 50* with particle size more than 43p) (Example 11) 10 4 93 20 7 99 30 9 100 45 11 100 60 14 100 For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as medium. 10 Table 21: Bioequivalence data of the composition of the invention against Art 50* with respect to pharmacokinetic parameters S.No Pharmacokinetic Art 50* Composition of the parameters invention 1 Cmax (pg/ml) 3.058 4.250 2 Tmax (h) 5.39 4.17 3 AUCo-t (pgh/ml) 22.688 25.659 4 AUCO(pgh/ml) 22.816 25.778 Table 22: Bioequivalence data with respect to Test (Composition of the invention) 15 to reference (Art 50*) Ratios (T/R ratios) at 90% Confidence Interval (C.I.) Pharmacokinetic 90% C.I. S.No Ratio % CV parameters Lower Upper 1 Cmax (pg/ml) 139.98 97.56 179.09 25.23 2 AUCo-t (pgh/ml) 113.09 89.48 150.17 22.39 3 AUCo(pgh/ml) 112.98 85.26 148.29 23.79 Example 12: 28 Table 23 Ingredients % w/w Part-I Diacerein 5-13 Lactose 10-50 Povidone 5-40 Docusate sodium 1-20 TPGS 5-30 Starch 10-50 Prosolv 5-70 Part-Il Dried Granules from Part I Eudragit 7.0 Part III Extra granular Prosolv 5-70 Ac-Di-Sol 1-15 Magnesium Stearate 0.1-3 Procedure: Docusate sodium was dissolved in purified water under stirring. Povidone was added under stirring to above solution of sodium docusate to form 5 a clear solution and further diacerein was added to form a uniform dispersion. The diacerein dispersion was passed through Dyno mill/Pressure homogenizer/ microfluidizer to get a suitable particle size. A clear solution of TPGS was added to above microparticulate/ nanoparticulate dispersion of diacerein. The diacerein dispersion was sprayed on starch and prosolv by top spray method on glatt. The 10 dried granules thus obtained were coated with Eudragit and further dried and mixed with prosolv, croscarmellose sodium and lubricated with magnesium stearate. The lubricated blend was filled in suitable size capsules. 15 Table 24: Dissolution data Time % Drug released (min) (Example 12) 5 26 10 44 15 75 30 97 45 98 60 98 29 Table 24 provides the dissolution data for diacerein capsules prepared as per the formula given in Table 23. For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 5 2C ± 0

.

5 2C was used as a medium. Example 13: Table 25 Ingredients %w/w Part-I Diacerein 5-13 Povidone 5-40 Docusate sodium 1-20 TPGS 5-30 Starch 10-50 Prosolv 5-70 Part-Il Dried Granules from Part I Eudragit 4.0 Part III Extra granular Prosolv 5-70 Ac-Di-Sol 1-15 Magnesium stearate 0.1-3 10 Procedure: Docusate sodium was dissolved in purified water under stirring. PVP was added under stirring to the above solution of sodium docusate to form a clear solution and further diacerein was added to form a uniform dispersion. The diacerein dispersion was passed through Dyno mill/Pressure homogenizer/microfluidizer to get a suitable particle size. A clear solution of TPGS 15 was added to above microparticulate/nanoparticulate dispersion of diacerein. The diacerein dispersion was sprayed on starch and prosolv by top spray method on glatt. The dried granules thus obtained were coated with Eudragit and further dried and mixed with prosolv, croscarmellose sodium and lubricated with magnesium stearate. The lubricated blend was filled in suitable size capsules. 30 Table 26: Dissolution data Time % Drug released (min) (Example-13) 5 32 10 56 15 75 30 85 45 90 60 94 Table 26 provides the dissolution data for diacerein capsules prepared as per the formula given in Table 25. For determination of drug release rate, USP Type 2 5 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as medium. Example 14: Table 27 Ingredients %w/w Part-I Diacerein 5-13 Povidone 5-40 Docusate sodium 1-20 TPGS 5-30 Sodium lauryl sulfate 1-20 Starch 10-50 Prosolv 5-70 Part-Il Dried Granules from Part I Eudragit 4.0 Part III Extra granular Prosolv SMCC 90 5-70 Ac-Di-Sol 1-15 Magnesium Stearate 0.1-3 10 Procedure: Docusate sodium was dissolved in purified water under stirring. PVP was added under stirring to the above solution of docusate sodium to form a clear solution and further diacerein was added to form a uniform dispersion. The diacerein dispersion was passed through Dyno mill/Pressure 31 homogenizer/microfluidizer to get a suitable particle size. A clear solution of TPGS & sodium lauryl sulfate was added to the above microparticulate/nanoparticulate dispersion of diacerein. The diacerein dispersion was sprayed on starch and prosolv by top spray method on glatt. The dried granules thus obtained were 5 coated with Eudragit and further dried and mixed with prosolv, croscarmellose sodium and lubricated with magnesium stearate. The lubricated blend was filled in suitable size capsules. 10 Table 28: Bioequivalence data of compositions of invention against Art 50* with respect to pharmacokinetic parameters. S. N. Pharmacokinetic Art 508 Composition of the parameters. invention 1 Cmax (pg/ml) 3.058 5.121 2 Tmax (h) 5.39 5.70 3 AUCo-t (pg.h/ml) 22.688 24.927 4 AUCo-inf (pg.h/ml) 22.816 25.569 Table 29: Bioequivalence data with respect to test (composition of the examples) 15 to reference (Art 50*) ratios (T/R ratios) at 90 % confidence interval. S. N. Pharmacokinetic Ratio 90 % C. I. % CV parameters Lower Upper 1 Cmax 120.17 107.61 134.2 13.33 2 AUCO-t 94.5 91.56 97.3 3.80 3 AUCo-inf 94.55 91.56 97.53 3.86 Example 15: Table 30 Ingredients %w/w Part-I Diacerein 5-13 Lactose 10-50 Povidone 5-40 Docusate sodium 1-20 TPGS 5-30 Starch 10-50 32 Prosolv 5-70 Part-A (Immediate release portion) Dried Granules (Portion containing 65-85% w/w of total diacerein of part 1) Part-B (Controlled release portion) Dried Granules (Portion containing 15%-35% w/w of total diacerein of part 1) Hydroxypropyl methyl cellulose 3.75 Prosolv 5-70 Magnesium Stearate 0.1-3 Extra granular Part A granules Part B granules Prosolv 5-70 Ac-Di-Sol 1-15 Magnesium Stearate 0.1-3 Procedure: Docusate sodium was dissolved in purified water under stirring. PVP was added under stirring to the above solution of sodium docusate to form a clear solution and further diacerein was added to form a uniform dispersion. The 5 diacerein dispersion was passed through Dyno mill/Pressure homogenizer/microfluidizer to get a suitable particle size. A clear solution of TPGS was added to the above microparticulate/nanoparticulate dispersion of diacerein. The diacerein dispersion was sprayed on starch and prosolv by top spray method on glatt. The dried granules thus obtained were divided into two parts. First part 10 (A) kept as such as an immediate release portion. To second part, hydroxypropylmethyl cellulose was added along with prosolv, mixed and lubricated with magnesium stearate. The lubricated granules were compacted through a roll compactor and the compacts were granulated through a multimill to get granules of uniform size (Part B). Part B granules were mixed with part A 15 granules along with prosolv, ac-di-sol and magnesium stearate and the final blend was filled in suitable size capsules. Table 31: Dissolution data Time % Drug released (min) (Example-15) 10 45 20 76 33 30 99 45 100 60 100 90 100 120 100 Table 31 provides the dissolution data for diacerein capsules prepared as per the formula given in Table 30. For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 5 2C ± 0

.

5 2C was used as medium. Example 16: Table 32 Ingredients %w/w Part-I Diacerein 5-13 Lactose 10-50 Povidone 5-40 Docusate sodium 1-20 TPGS 5-30 Starch 10-50 Prosolv 5-70 Part-A (Immediate release portion) Dried Granules (Portion containing 65-85% w/w of total diacerein of part 1) Part-B (Controlled release portion) Dried Granules (Portion containing 15%-35% w/w of total diacerein of part 1) Hydroxypropyl methyl cellulose 7.5 Prosolv 5-70 Magnesium Stearate 0.1-3 Extra granular Part A granules Part B granules Prosolv 5-70 Ac-Di-Sol 1-15 Magnesium Stearate 0.1-3 Procedure: Docusate sodium was dissolved in purified water under stirring. PVP 10 was added under stirring to the above solution of sodium docusate to form a clear solution and further diacerein was added to form a uniform dispersion. The 34 diacerein dispersion was passed through Dyno mill/Pressure homogenizer/microfluidizer to get a suitable particle size. A clear solution of TPGS was added to the above microparticulate/nanoparticulate dispersion of diacerein. The diacerein dispersion was sprayed on starch and prosolv by top spray method 5 on glatt. The dried granules thus obtained were divided into two parts. First part was (A) kept as such as an immediate release portion. To second part, hydroxypropylmethyl cellulose was added along with prosolv, mixed and lubricated with magnesium stearate. The lubricated granules were compacted through a roll compactor and the compacts were granulated through a multimill to 10 get granules of uniform size (Part B). Part B granules were mixed with part A granules along with prosolv, ac-di-sol and magnesium stearate and the final blend was filled in suitable size capsules. Table 33: Dissolution data Time (min) % Drug released (Example 16) 10 11 20 24 30 36 45 51 60 72 90 92 120 95 15 Table 33 provides the dissolution data for diacerein capsules prepared as per the formula given in Table 32. For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 2C ± 0 .52C was used as medium. 20 Example 17: Table-34 Ingredients %w/w Part-I Diacerein 5-13 Lactose 10-50 Povidone 5-40 Docusate sodium 1-20 TPGS 5-30 Starch 10-50 35 Prosolv 5-70 Part-A (Immediate release portion) Dried Granules (Portion containing 65-85% w/w of total diacerein of part 1) Part-B (Controlled release portion) Dried Granules (Portion containing 15%-35% w/w of total diacerein of part 1) Hydroxypropyl methyl cellulose 6.25 Prosolv 5-70 Magnesium Stearate 0.1-3 Part-IV (Extra granular) Part II granules Part III granules Prosolv 5-70 Ac-Di-Sol 1-15 Magnesium Stearate 0.1-3 Procedure: Docusate sodium was dissolved in purified water under stirring. PVP was added under stirring to the above solution of sodium docusate to form a clear solution and further diacerein was added to form a uniform dispersion. The 5 diacerein dispersion was passed through Dyno mill/Pressure homogenizer/microfluidizer one or more times to get a suitable particle size. A clear solution of TPGS was added to the above microparticulate/nanoparticulate dispersion of diacerein. The diacerein dispersion was sprayed on starch and prosolv by top spray method on glatt. The dried granules thus obtained were 10 divided into two parts. First part (A) was kept as such as an immediate release portion. To second part, hydroxypropylmethyl cellulose was added along with prosolv, mixed and lubricated with magnesium stearate. The lubricated granules were compacted through a roll compactor and the compacts were granulated through a multimill to get granules of uniform size (Part B). Part B granules were 15 mixed with part A granules along with prosolv, ac-di-sol and magnesium stearate and the final blend was filled in suitable size capsules. Table 35: Dissolution data Time (min) % Drug released (Example-17) 10 24 20 43 30 62 45 80 36 60 90 90 100 120 100 Table 35 provides the dissolution data for diacerein capsules prepared as per the formula given in Table 34. For determination of drug release rate, USP Type 2 Apparatus (rpm 75) was used wherein 1000 ml of pH 5.7 phosphate buffer at 37 5 2C ± 0 .5 2C was used as a medium. Table 36: Bioequivalence data of composition of the invention against Art 50* with respect to pharmacokinetic parameters. S. N. Pharmacokinetic Art 508 Composition of the parameters invention 1 Cmax (pg/ml) 3.058 4.773 2 Tmax (h) 5.39 4.44 3 AUCO-t (pg.h/ml) 22.688 21.651 4 AUCo-inf (pg.h/ml) 22.816 22.192 10 Table 37: Bioequivalence data with respect to test (composition of the invention) to reference (Art 50*) ratios (T/R ratios) at 90 % confidence interval. S. N. Pharmacokinetic Ratio 90 % C. I. % CV parameters Lower Upper 1 Cmax 122.63 110.76 135.78 11.15 2 AUCO-t 94.89 89.71 100.36 6.13 3 AUCO inf 94.73 89.34 100.45 6.41 15 While the invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention. Where the terms "comprise", "comprises", "comprised" or "comprising" are used in 20 this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof. 37 Further, any prior art reference or statement provided in the specification is not to be taken as an admission that such art constitutes, or is to be understood as constituting, part of the common general knowledge in Australia. 38

Claims (5)

1. Use of rhein or diacerein, or salts or esters thereof, for the manufacture of a medicament for the treatment of osteoarthritis, wherein the said medicament is adapted for administration in a dosage form which comprises from about 20mg to about 45mg of rhein or diacerein, or salts or esters or prodrugs thereof to a patient according to a dosage regimen comprising a dosing interval of twice daily from day one of therapy.

2. The use of claim 1, wherein the dosage form comprises one or more of a tablet, capsule, powder, disc, caplet, granules, pellets, granules in capsule, minitablets, minitablets in capsule, pellets in capsule, and sachet.

3. The use of claim 1, wherein the dosage form further comprises one or more pharmaceutically acceptable excipients comprising fillers, lubricants, disintegrants, surfactants and glidants.

4. The use of claim 1, wherein the dosage form can be taken with or without food.

5. The use of any one of claims 1 to 4, substantially as hereinbefore described. 39